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Abstract 
Purpose : Autosomal-recessive bestrophinopathy (ARB) is a distinct inherited bestrophinopathy that 
is caused by mutations in bestrophin 1 (BEST1), a protein located in the retinal pigment epithelium 
(RPE). The p.R200X mutation is a premature stop mutation that causes alterations in the RPE and 
subretinal deposits in the macular area. Patients with this mutation have an absent EOG light rise 
and reduced ERGs, presenting with central vision loss early in life. Currently, patients with 
bestrophinopathies, such as ARB, do not have any available treatments and visual loss cannot be 
prevented. Resolving the exact function of the bestrophin 1 in RPE cells is an essential step in 
identifying viable therapeutics for these patient groups. Here we are using induced pluripotent stem 
cell (iPSC)-derived RPE created from a patient with the p.R200X mutation to investigate the role of 
BEST1 in the RPE. 
 
Methods : We have created iPSCs from p.R200X patient fibroblasts by reprogramming with episomal 
vectors (c-myc, Klf4, Lin28, Oct4, Sox2). iPSC colonies were isolated, expanded and differentiated 
into RPE by spontaneous differentiation method. After approximately 6 weeks pigmented foci were 
purified by manual dissection and cells seeded to encourage monolayer formation. Patient iPSC and 
iPSC-derived RPE cells were assessed by standard molecular and cellular protocols, including 
immunocytochemistry (ICC) and PCR, in comparison to control cells, and whole cell patch clamp was 
used to assess RPE cell function. 
 
Results : Sequencing of the starting material confirmed presence of pR200X mutation in the patient 
line. Whilst immunocytochemistry revealed absence of BEST1 protein in the pR200X patient iPS-RPE 
cells, confirming true null BEST1 mutation. Our patch clamp experiments confirmed involvement of 
BEST1 in the ion currents of the pR200X patient iPS-RPE cells. 
Our results suggest that BEST1 may be involved in volume regulation within the RPE. Morphological 
assessment of the pR200X patient iPS-RPE revealed significant difference in size, in comparison to 
the control iPS-RPE cells. 
 
Conclusions : Examination of the p.R200X mutation in patient derived iPSC-RPE cells has provided 
new insight into the role of BEST1 in the RPE cell. A greater understanding of the effects of BEST1 
mutations on pathological mechanisms will assist the development of novel therapeutics for 
bestrophinopathy patients. 
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